Expression and prognostic value of plasminogen activator inhibitor type 1 in node-negative breast cancer  

作　　者：Bin Wang Ning Wang Chunyan Xue Bin Jiang Yajie Wang 

机构地区：[1]Department of Oncology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China [2]Department of Oncology, The Third People＇s Hospital Affiliated to Jiao Tong University, Shanghai 201900, China

出　　处：《The Chinese-German Journal of Clinical Oncology》2008年第6期339-343,共5页中德临床肿瘤学杂志（英文版）

基　　金：Research Programme of the Shanghai Municipal Science and Technology Commission(No.06DZ19505)

摘　　要：Objective： To investigate the expressions of plasminogen activator inhibitor type 1 （PAl-1）, C-erbB-2, VEGF and Ki-67 by immunohistostaining and then to evaluate the prognostic value of PAl-1 in node-negative breast cancer. Methods： The study included a retrospective series of 62 female patients with axillary lymph node-negative breast cancer. Expressions of PAl-1, C-erbB-2, VEGF and Ki-67 were determined by immunohistostaining on formalin-fixed paraffin-embedded tissue sections from these patients after a median follow-up of 69 months （range 22-117 months）. Correlations with well known clinicopathologic factors were assessed and multivariate survival analyses were performed. Results： High PAl-1 level was positively associated with high histologic grade of the tumors. Disease-free survival （DFS） was significantly shorter for the patients with moderate to intensive expression of PAl-1 than for those with negative （χ^2 = 25.46, P 〈 0.001; χ^2 = 23.07, P 〈 0.001） to mild expression （χ^2 = 19.75, P 〈 0.001; χ^2 = 17.40, P 〈 0.001）. Although on univariate analysis of the prognostic factors, tumor size, location of primary tumor and age as well as expressions of PAl-1, VEGF and Ki-67 were all significantly prognostic factors for DFS （P 〈 0.05）, PAl-1 was the only independent prognostic factor on multivariate analysis （P 〈 0.0001; hazard ratio [HR], 4.041; 95% confidence interval [CI], 1.928-8.468）. Conclusion： These results of the current study indicate that intermediate or high expression of PAl-1 represents a strong and independent unfavorable prognostic factor for the development of recurrence or metastases in axillary node-negative breast cancer.

关 键 词：breast carcinoma NODE-NEGATIVE plasminogen activator inhibitor type 1 （PAl-1） PROGNOSIS 

分 类 号：R737.9[医药卫生—肿瘤]